

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Wu, et al.	Confirmation No.:	3434
Serial No.:	10/781,442	Art Unit:	1626
Filed:	February 18, 2004	Examiner:	Grazier, Nyeemah
For:	Phenylenediamine Urotensin-II Receptor Antagonists and CCR-9 Antagonists	Attorney Docket No.:	017092-0046-999

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT IN REPLY TO ACTION OF DECEMBER 13, 2006**

Sir:

In response to the Office Action mailed December 13, 2006, Applicants request entry of this Amendment into the file of the above-identified application and consideration of the remarks below.

Submitted concurrently herewith are:

- (A) A Petition for Extension of Time for three (3) Months;
- (B) A supplemental information disclosure statement along with a list of references;
- (C) An unexecuted Declaration of Robert Market under 37 CFR 1.132 (An executed Declaration will be provided under separate cover.);
- (D) A Petition For Correction of Inventorship Under 37 C.F.R. §1.48(a);
- (E) A Consent of Assignee to Change Inventorship Under 37 C.F.R. §1.48(a) and Statement Under 37 C.F.R. § 3.73(b);
- (F) Statements from Inventors (5) in Support of Petition for Correction of Inventorship; and
- (G) Declarations from Correct Inventors

**Amendments to the Inventors** begins on page 2 of this paper,

**Complete listing of claims** beginning on page 3;

**Remarks** beginning on page 6.